On Jan. 1, Dave Ricks becomes CEO of drugmaker Eli Lilly and Co. as it tries to launch new products after a tough stretch of patent expirations. To prepare, Ricks has spent a lot of time with outgoing CEO John Lechleiter “learning from the master.”
Dozens of companies across central Indiana are using programs aimed at middle- and high-school students to develop a pool of talented kids who are interested in science, technology, engineering and math to fill the growing number of jobs for which such skills are necessary.
Eli Lilly and Co. is pledging $90 million over five years to improve access to treatment for diabetes, cancer and tuberculosis in developing countries—the latest push in its philanthropic strategy of building health care systems around the world and increasing the market for its prescription drugs.
The residents who sued sought to revoke the school’s property-tax exemption, in part because Princeton shares commercial royalties with faculty from a patent that Indianapolis-based Eli Lilly and Co. turned into the cancer drug Alimta.
Pharma giant Novo Nordisk announced Thursday that it is cutting 1,000 jobs after slashing forecasts for 2016, citing lower prices for diabetes drugs. Novo and competitors such as Indianapolis-based Eli Lilly will likely have to keep tightening their belts as prices and profit margins fall, experts say.